Program
Doxorubicin
Also written as “doxorubicin hydrochloride”, “Doxorubicin hydrochloride (liposomal)” and “doxorubicin”.
Its studies are mostly in Breast Neoplasms · Sarcoma · Lymphoma, Large B-Cell, Diffuse · Carcinoma, Hepatocellular · Sarcoma, Kaposi, led by 16 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 50 open or running | phase 2since Jan 25, 2005 | Jan 25, 2005 | none ahead |
| Johnson & Johnson | 40 open or running | phase 3since Feb 9, 2005 | Jan 31, 2005 | none ahead |
| Sanofi | 40 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Sequus Pharmaceuticals | 40 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Amgen | 30 open or running | phase 3since Mar 31, 2003 | Jul 5, 2000 | none ahead |
| InSightec | 22 open or running | phase 2since Nov 7, 2022 | Nov 7, 2022 | none ahead |
| Philogen | 20 open or running | phase 2since May 25, 2010 | May 25, 2010 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 2since Oct 24, 2005 | Oct 24, 2005 | none ahead |
| alfacell | 10 open or running | phase 3since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| bio-cancer-treatment-international-limited | 10 open or running | phase 1since Sep 30, 2009 | Sep 30, 2009 | none ahead |
| presage-biosciences | 10 open or running | phase 1since Jan 22, 2017 | Jan 22, 2017 | none ahead |
| sopherion-therapeutics | 10 open or running | phase 3since Feb 17, 2006 | Feb 17, 2006 | none ahead |
| spirovant-sciences-inc | 11 open or running | phase 2since Jul 18, 2024 | Jul 18, 2024 | Dec 31, 2026phase 2 · NCT06526923 |
| sutphin-drugs | 10 open or running | early phase 1since Jun 3, 2019 | Jun 3, 2019 | none ahead |
| Valerio Therapeutics | 10 open or running | phase 3since Jul 26, 2012 | Jul 26, 2012 | none ahead |
| zivena | 10 open or running | phase 2since May 11, 2004 | May 11, 2004 | none ahead |
Also a collaborator on its studies: AbbVie and PharmaMar.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Nov 1, 1999.
- Aug 16, 2006Phase 2 study in Breast NeoplasmsSanofi · NCT00365365 · 214 enrolled · United States
- Apr 17, 2007Phase 2 study in Carcinoma, DuctalSanofi · NCT00461344 · 20 enrolled
- Sep 30, 2009bio-cancer-treatment-international-limited's first study: phase 1 study in NeoplasmsNew to bio-cancer-treatment-international-limitedbio-cancer-treatment-international-limited · NCT00988195 · 15 enrolled · Hong Kong
- May 25, 2010Philogen's first study: phase 2 study in Breast NeoplasmsNew to PhilogenPhilogen · NCT01131364 · 29 enrolled · Italy
- Jul 26, 2012Valerio Therapeutics's first study: phase 3 study in Carcinoma, HepatocellularNew to Valerio TherapeuticsValerio Therapeutics · NCT01655693 · 397 enrolled · United States, Austria, Belgium and more
- Mar 14, 2013Phase 1 study in NeoplasmsJohnson & Johnson · NCT01815294 · 54 enrolled · United States, Belgium, Spain and more
- Feb 24, 2014Phase 1 study in SarcomaPhilogen · NCT02076620 · 29 enrolled · Germany, Italy
- Jan 29, 2016Phase 1 study in Neoplasm MetastasisEli Lilly · NCT02677116 · 68 enrolled · United States, Japan
- May 24, 2016Phase 1 study in SarcomaEli Lilly · NCT02783599 · 51 enrolled · United States, France, Italy and more
- Jan 22, 2017presage-biosciences's first study: phase 1 study in SarcomaNew to presage-biosciencespresage-biosciences · NCT03056599 · 23 enrolled · United States
- Sep 13, 2017Phase 1 study in SarcomaEli Lilly · NCT03283696 · 24 enrolled · United States, Germany, Italy
- Jun 3, 2019sutphin-drugs's first study: early phase 1 study in Lymphoma LeukemiaNew to sutphin-drugssutphin-drugs · NCT03975205 · 500 enrolled · India
- Nov 7, 2022InSightec's first studies: 2 phase 2 studies in Brain NeoplasmsNew to InSightecInSightec · NCT05615623, NCT05630209
- Jul 18, 2024spirovant-sciences-inc's first study: phase 2 study in Cystic FibrosisNew to spirovant-sciences-incspirovant-sciences-inc · NCT06526923 · 15 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Cystic Fibrosisspirovant-sciences-inc · NCT06526923
TargetBeta
“DNA topoisomerase II alpha inhibitor; DNA inhibitor”ChEMBL 37, by rule
Other programs on TOP2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Etoposiderule | Hoffmann-La Roche | phase 3 | 28 |
| amrubicinrule | Bristol-Myers Squibb | phase 3 | 9 |
| Daunorubicinrule | kura-oncology-inc | phase 3 | 7 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06526923Cystic Fibrosis · United States | 2 | Recruiting | spirovant-sciences-inc | Dec 31, 2026 | 15 |
| NCT05630209Brain Neoplasms · United States | 2 | Active, not recruiting | InSightec | Jun 2026 | 10 |
| NCT05615623Brain Neoplasms · Canada | 2 | Active, not recruiting | InSightec | Jun 2026 | 10 |
| NCT03975205Lymphoma Leukemia · India | Early 1 | UNKNOWN | sutphin-drugs | Oct 31, 2019 | 500 |
| NCT03283696Sarcoma · United States, Germany, Italy | 1 | Completed | Eli Lilly | Apr 29, 2019 | 24 |
| NCT03056599Sarcoma · United States | 1 | Completed | presage-biosciences | Jul 22, 2021 | 23 |
| NCT02783599Sarcoma · United States, France, Italy and more | 1 | Completed | Eli Lilly | Jul 5, 2018 | 51 |
| NCT02677116Neoplasm Metastasis · United States, Japan | 1 | Completed | Eli Lilly | Oct 10, 2018 | 68 |
| NCT02076620Sarcoma · Germany, Italy | 1 | Completed | Philogen | Jan 25, 2018 | 29 |
| NCT01815294Neoplasms · United States, Belgium, Spain and more | 1 | Completed | Johnson & Johnson | Dec 2014 | 54 |
| NCT01655693Carcinoma, Hepatocellular · United States, Austria, Belgium and more | 3 | Completed | Valerio Therapeutics | May 2017 | 397 |
| NCT01131364Breast Neoplasms · Italy | 2 | Terminated | Philogen | Mar 2012 | 29 |
| NCT00988195Neoplasms · Hong Kong | 1 | Completed | bio-cancer-treatment-international-limited | Aug 2009 | 15 |
| NCT00461344Carcinoma, Ductal | 2 | Terminated | Sanofi | Jun 2005 | 20 |
| NCT00365365Breast Neoplasms · United States | 2 | Completed | Sanofi | Oct 2011 | 214 |
| NCT00312208Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Oct 2008 | 3,299 |
| NCT00294996Breast Neoplasms · United States, Argentina, Canada and more | 3 | UNKNOWN | sopherion-therapeutics | 363 | |
| NCT00250874Breast Neoplasms · Italy | 2 | UNKNOWN | Teva Pharmaceutical Industries | 45 | |
| NCT00244127Aggressive Non-Hodgkin's Lymphoma in the Elderly. · France, Germany, Italy and more | 2 | UNKNOWN | Teva Pharmaceutical Industries | 75 | |
| NCT00216645Ovarian Neoplasms | 2 | Completed | Johnson & Johnson | 74 | |
| NCT00191789Breast Neoplasms · India | 2 | Completed | Eli Lilly | Apr 2009 | 65 |
| NCT00115414Breast Neoplasms | 2 | Completed | Amgen | ||
| NCT00103506Multiple Myeloma · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | May 2014 | 646 |
| NCT00102609Sarcoma | 1 | Completed | Johnson & Johnson | 41 | |
| NCT00102219Breast Neoplasms · Brazil, Greece, Hungary and more | 2 | Completed | Eli Lilly | 77 | |
| NCT00082472Neoplasm Metastasis · United States | 2 | UNKNOWN | zivena | 30 | |
| NCT00057382Carcinoma, Hepatocellular · United States, Brazil, China and more | 3 | Terminated | Amgen | 750 | |
| NCT00021255Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Dec 2014 | 3,222 |
| NCT00005960Pain · United States | 2 | UNKNOWN | Amgen | ||
| NCT00002319Sarcoma, Kaposi · United States | 3 | Completed | Sequus Pharmaceuticals | ||
| NCT00002318Sarcoma, Kaposi · United States | 3 | UNKNOWN | Sequus Pharmaceuticals | 225 | |
| NCT00002147Sarcoma, Kaposi · United States | 3 | Completed | Sequus Pharmaceuticals | ||
| NCT00002105Sarcoma, Kaposi · United States | 3 | Completed | Sequus Pharmaceuticals | 220 | |
| NCT00003034Mesothelioma, Malignant · United States, Germany, Italy and more | 3 | UNKNOWN | alfacell | Feb 2008 | 300 |
How it is read
Names in the registry
- “Doxorubicin”, 29 entries
- “doxorubicin hydrochloride”, 6 entries
- “Doxorubicin hydrochloride (liposomal)”, 4 entries
- “doxorubicin”, 3 entries
- “CHOP”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 15 studies
- Sarcoma, 8 studies
- Lymphoma, Large B-Cell, Diffuse, 5 studies
- Carcinoma, Hepatocellular, 4 studies
- Sarcoma, Kaposi, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.